Zacks Investment Research Upgrades Vivos Therapeutics (NASDAQ:VVOS) to Hold

Vivos Therapeutics (NASDAQ:VVOSGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

Separately, Craig Hallum decreased their price objective on Vivos Therapeutics to $5.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th.

NASDAQ VVOS traded up $0.12 during trading hours on Wednesday, reaching $1.45. 50,129 shares of the company’s stock were exchanged, compared to its average volume of 1,411,337. The stock has a market cap of $33.37 million, a PE ratio of -1.38 and a beta of 0.83. Vivos Therapeutics has a one year low of $1.18 and a one year high of $7.09. The firm has a fifty day moving average of $1.96 and a 200-day moving average of $2.45.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in shares of Vivos Therapeutics in the 3rd quarter valued at $188,000. BlackRock Inc. lifted its stake in shares of Vivos Therapeutics by 255.8% in the 3rd quarter. BlackRock Inc. now owns 48,905 shares of the company’s stock valued at $198,000 after purchasing an additional 35,158 shares during the period. Blueshift Asset Management LLC acquired a new position in shares of Vivos Therapeutics in the 3rd quarter valued at $76,000. Geode Capital Management LLC lifted its stake in shares of Vivos Therapeutics by 55.0% in the 3rd quarter. Geode Capital Management LLC now owns 73,851 shares of the company’s stock valued at $298,000 after purchasing an additional 26,190 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Vivos Therapeutics in the 3rd quarter valued at $636,000. Hedge funds and other institutional investors own 9.81% of the company’s stock.

Vivos Therapeutics Company Profile (Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Featured Articles

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.